GAinPD

Acrónimo: GAinPD_SC01

Objetivo temático: Parkinson disease (PD), the second most common neurodegenerative disease, is fast growing and is presently a major public health problem partly as result of a rapid and substantial rise in global life expectancy and the existence of increasingly aged populations. Currently available treatments show only modest symptomatic efficacy, leaving an unmet medical need for new and effective therapies. For more than thirty years it has been understood that inflammatory changes occur in the blood and brain of PD patients, but only in the last few years has inflammation been viewed as part of the progressive nature of the disease and not just a result of the disease. Additionally, recent data highlights that the changes in the bacterial composition in the gut of people with PD may trigger inflammation in the gut which fuels the disease. A seminal hypothesis was recently proposed for PD etiology where gut dysbiosis could trigger PD if systemic inflammation acting as a facilitator was present.

Área Científica: Neurociências, Imunologia, Microbiologia

Síntese do Projeto: We propose that averting gut and systemic inflammation will prevent the progression of the pathology to the CNS. Nevertheless, all clinical trials using conventional anti-inflammatory drug failed to arrest or delay PD progression. Our project adopts a preclinical trial study since we aim to validate new promising anti-inflammatory candidates to arrest gut-first PD.

Investigador Responsável na UC: Sandra Isabel Morais de Almeida Costa Cardoso

Unidade Orgânica UC: Reitoria - CNC

Instituições participantes no Projeto: Universidade de Coimbra - Instituição Proponente

Instituição Financiadora/Gestora: Cure Parkinson's (CP)

Programa de Financiamento: Cure Parkinson's (CP) - Apply for funding 2022

Período de execução: 01/04/2023 a 31/03/2026 (36 meses)

Custo total elegível (EUR): 249.823,00 £

Técnico do Projeto: Kayleigh Mikaela Oliveira Rodrigues

Contacto: kayleigh.rodrigues@uc.pt | 239247021 (Ext 210021)